The US Food & Drug Administration (FDA) has cleared an investigational new drug (IND) application for SpliceBio’s lead programme SB-007, a clinical-stage therapeutic addressing the root genetic cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations. The SpliceBio study uses protein splicing to address diseases caused by mutations in […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!